Remedy Pharmaceuticals Inc.
Industry
- Pharmaceuticals
- Vaccines
- Specialty Pharmaceuticals
- Biotechnology
Latest on Remedy Pharmaceuticals Inc.
Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Cycle Offers $466m For Vanda, Which Tur
Biogen, Inc. underscored its commitment to Alzheimer’s disease while announcing the discontinuation of three clinical-stage development programs as new CEO Christopher Viehbacher continues to piece t
With analysts watching Biogen Inc. closely for signs of a major deal, the US biotech has instead taken a little step down the merger and acquisition pathway by inking an option agreement to acquire
Low and high doses of Biogen 's MS therapy Tysabri (natalizumab) have missed primary and secondary efficacy endpoints in the Phase IIb ACTION 2 study which was evaluating its use in acute ischemi